Figure 2

PET/CT images of ¹⁸ F-FDG and ¹²⁴ I-IAZGP in a head and neck cancer patient. (A to D) Coronal maximum intensity projection PET images of ¹⁸F-FDG acquired 3 days before ¹²⁴I-IAZGP administration (A) and ¹²⁴I-IAZGP acquired at 3 h (B), 6 h (C), and 27 h (D) post-administration in a patient with head and neck cancer. (E to G) Cross-sectional fused PET/CT images of the same patient comparing ¹⁸ F-FDG (E and F left, G top) with ¹²⁴I-IAZGP at 6 h (E and F right, G bottom). No evidence of ¹²⁴I-IAZGP uptake is seen in either the FDG-avid supraglottic larynx cancer or the approximately 2-cm lymph node. The clearance of ¹²⁴I-IAZGP is similar to that seen in Figure 1, with a symmetric distribution of physiologic ¹²⁴I in the salivary glands. Note that image intensities are not directly comparable and that the ¹⁸F-FDG image was acquired in the radiotherapy treatment position with the patient in a facial mask.